ImmunityBio, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.20 | -$0.20 | -$0.20 |
Q2 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
Q3 2024 | 1 | -$0.18 | -$0.18 | -$0.18 |
Q4 2024 | 2 | -$0.29 | -$0.15 | -$0.22 |
Q1 2025 | 1 | -$0.13 | -$0.13 | -$0.13 |
Q2 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
Q3 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
Q4 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
Q1 2026 | 1 | -$0.04 | -$0.04 | -$0.04 |
Q2 2026 | 1 | -$0.03 | -$0.03 | -$0.03 |
Q3 2026 | 1 | -$0.04 | -$0.04 | -$0.04 |
Q4 2026 | 1 | -$0.05 | -$0.05 | -$0.05 |
Q1 2027 | 1 | $0.17 | $0.17 | $0.17 |
Q2 2027 | 1 | $0.18 | $0.18 | $0.18 |
Q3 2027 | 1 | $0.18 | $0.18 | $0.18 |
Q4 2027 | 1 | $0.18 | $0.18 | $0.18 |
Q1 2028 | 1 | $0.53 | $0.53 | $0.53 |
Q2 2028 | 1 | $0.59 | $0.59 | $0.59 |
Q3 2028 | 1 | $0.58 | $0.58 | $0.58 |
Q4 2028 | 1 | $0.60 | $0.60 | $0.60 |
ImmunityBio, Inc. Earnings Date And Information
ImmunityBio, Inc. last posted its earnings results on Monday, August 12th, 2024. The company reported $-0.2 earnings per share for the quarter, missing analysts' consensus estimates of $-0.17 by $0.03. The company had revenue of 6.11 M for the quarter and had revenue of 622,000 for the year. ImmunityBio, Inc. has generated $-1 earnings per share over the last year ($-1.15 diluted earnings per share) and currently has a price-to-earnings ratio of -5.61. ImmunityBio, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based on prior year's report dates.
ImmunityBio, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/12/2024 | Q3 2024 | -$0.14 | $2.93 M | $6.11 M | ||
08/12/2024 | Q2 2024 | -$0.17 | -$0.20 | -0.03 | $14.71 M | $1.05 M |
05/09/2024 | Q1 2024 | -$0.16 | -$0.20 | -0.04 | $40,000 | |
03/19/2024 | Q4 2023 | -$0.18 | -$0.35 | -0.17 | $139,000 | |
11/08/2023 | Q3 2023 | -$0.19 | $82,000 | |||
08/08/2023 | Q2 2023 | -$0.26 | -$0.32 | -0.06 | $41,000 | |
05/11/2023 | Q1 2023 | -$0.27 | -$0.35 | -0.08 | $360,000 | |
03/01/2023 | Q4 2022 | -$0.22 | -$0.27 | -0.05 | $73,000 | |
11/08/2022 | Q3 2022 | -$0.23 | -$0.28 | -0.05 | $118,000 | $118,000 |
08/08/2022 | Q2 2022 | -$0.24 | -$0.24 | 0 | $25,000 | $35,000 |
05/10/2022 | Q1 2022 | -$0.22 | -$0.26 | -0.04 | $14,000 | |
03/01/2022 | Q4 2021 | -$0.21 | -$0.23 | -0.02 | $390,000 | |
11/12/2021 | Q3 2021 | -$0.20 | -$0.22 | -0.02 | $25,000 | $66,000 |
08/12/2021 | Q2 2021 | -$0.12 | -$0.23 | -0.11 | $25,000 | $339,000 |
05/14/2021 | Q1 2021 | -$0.41 | -$0.21 | 0.2 | $139,000 | |
03/04/2021 | Q4 2020 | -$0.18 | -$0.18 | 0 | $-147,000 | |
11/09/2020 | Q3 2020 | -$0.18 | -$0.17 | 0.01 | $7,500 | $151,000 |
08/07/2020 | Q2 2020 | -$0.19 | -$0.13 | 0.06 | $7,500 | $436,000 |
05/11/2020 | Q1 2020 | -$0.17 | -$0.10 | 0.07 | $165,000 | |
03/25/2020 | Q4 2019 | -$0.20 | -$0.07 | 0.13 | $920,000 |
ImmunityBio, Inc. Earnings: Frequently Asked Questions
-
When is ImmunityBio, Inc.'s earnings date?
ImmunityBio, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based off last year's report dates.
-
How can I listen to ImmunityBio, Inc.'s earnings conference call?
The conference call for ImmunityBio, Inc.'s latest earnings report can be listened to online.
-
How can I read ImmunityBio, Inc.'s conference call transcript?
The conference call transcript for ImmunityBio, Inc.'s latest earnings report can be read online.
-
How much revenue does ImmunityBio, Inc. generate each year?
ImmunityBio, Inc. (:IBRX) has a recorded annual revenue of $622,000.
-
How much profit does ImmunityBio, Inc. generate each year?
ImmunityBio, Inc. (:IBRX) has a recorded net income of $622,000. ImmunityBio, Inc. has generated $-1.15 earnings per share over the last four quarters.
-
What is ImmunityBio, Inc.'s price-to-earnings ratio?
ImmunityBio, Inc. (:IBRX) has a price-to-earnings ratio of -5.61 and price/earnings-to-growth ratio is -0.75.